Pulmonary fibrosis secondary to COVID-19
Conditions
Interventions
Pirfenidone group:Based on the basic treatment given to the control group, the initial dose of pirfenidone was titrated gradually to 400mg tid from 100mg tid for maintenance treatment.
Nidanib group:In addition to the basic treatment given to the control group, the patients were given Nidanib 100-150mg bid maintenance therapy according to their weight and tolerance.
Control group:Only conventional oxygen therapy and pulmonary rehabilitation therapy were given, in addition to basic therapeutic measures such as relieving cough and reducing phlegm drugs were allowed
Sponsors
Fujian Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years old; 2. Patients with novel coronavirus infection: According to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10th Edition) released in January 2023, patients diagnosed with novel coronavirus infection after admission; 3. Pulmonary fibrosis was found in the patient's computed tomography of chest (determined jointly by two specialists above the deputy director of the imaging department).
Exclusion criteria
Exclusion criteria: 1. COVID-19 infection without pneumonia; 2. Mild to medium COVID-19 patients with no abnormal changes in chest images reexamined 1 month later; 3. Patients who died before the start of follow-up; 4. Patients who cannot cooperate because of mental disorders, dementia or other reasons; 5. Patients with pulmonary fibrosis before COVID-19 infection; 6. Patients with advanced tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycochain antigen KL-6;Lung function;Chest Computed Tomography scan; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dyspnea mMRC scale;SF-36;6-minute walking test;Inflammatory cytokines (TNF-a, IL-8, IL-17A, IL-17D, etc.); | — |
Countries
China
Contacts
Public ContactHongru Li
Fujian Provincial Hospital
Outcome results
None listed